Christophe Debuy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Christophe Debuy has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Désirée Y. van Haaften-Visser
Centre of Lysosomal and Metabolic Diseases, Department of Paediatrics Erasmus Medical Centre Rotterdam the Netherlands
2 shared publications Alice S. Brooks
Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
1 shared publicationBastiaan T. van Dijk
Department of Paediatrics, Willem-Alexander Children’s Hospital, Division of Neonatology, Leiden University Medical Centre, Leiden, the Netherlands
1 shared publication- Bianca M. de Graaf
Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
1 shared publication C. J. Klein‐De Ronde
Centre of Lysosomal and Metabolic Diseases, Department of Clinical Genetics Erasmus Medical Centre Rotterdam the Netherlands
1 shared publicationD. Vos
Centre of Lysosomal and Metabolic Diseases, Department of Clinical Genetics Erasmus Medical Centre Rotterdam the Netherlands
1 shared publication
Latest Publications
- Open Access
- 9 November 2026
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 49 (6)
Bringing Untargeted Metabolomics to the Clinic: Real‐World Data and Implementation for Screening of Inherited Metabolic Diseases
Inherited metabolic diseases (IMD) require timely diagnosis since a considerable number of these disorders respond to early treatment. Traditional metabolic screening relies on multiple targeted assays guided by clinical symptoms, making it laborious and potentially increasing the risk of underdiagnosis. Untargeted metabolomics provides broader biochemical coverage, but evidence of its diagnostic performance is limited. In this metabolomics implementation study, we analysed 484 plasma samples submitted for routine metabolic screening using both targeted assays and metabolomics in parallel. The results of these analyses were independently interpreted by two laboratory specialists and results were compared. Overall, 85.5% concordance was achieved between the two approaches. The majority of discrepancies stem from aberrant biomarkers traditionally measured in urine observed in metabolomics but not in the targeted plasma analyses. Importantly, inconclusive results requiring follow up were equally observed among the two methods. Metabolomics screening resulted in the detection of one new and one tentative IMD, which were not detected by targeted tests. Collectively, these results support the application of untargeted metabolomics for IMD screening in clinical practice. In addition to our study results, we share our detailed protocol and workflow towards implementation of untargeted metabolomics in clinical practice to facilitate broader use of diagnostic metabolomics in the IMD community.
- 9 November 2026
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 49 (6)
Open AccessBringing Untargeted Metabolomics to the Clinic: Real‐World Data and Implementation for Screening of Inherited Metabolic Diseases
Inherited metabolic diseases (IMD) require timely diagnosis since a considerable number of these disorders respond to early treatment. Traditional metabolic screening relies on multiple targeted assays guided by clinical symptoms, making it laborious and potentially increasing the risk of underdiagnosis. Untargeted metabolomics provides broader biochemical coverage, but evidence of its diagnostic performance is limited. In this metabolomics implementation study, we analysed 484 plasma samples submitted for routine metabolic screening using both targeted assays and metabolomics in parallel. The results of these analyses were independently interpreted by two laboratory specialists and results were compared. Overall, 85.5% concordance was achieved between the two approaches. The majority of discrepancies stem from aberrant biomarkers traditionally measured in urine observed in metabolomics but not in the targeted plasma analyses. Importantly, inconclusive results requiring follow up were equally observed among the two methods. Metabolomics screening resulted in the detection of one new and one tentative IMD, which were not detected by targeted tests. Collectively, these results support the application of untargeted metabolomics for IMD screening in clinical practice. In addition to our study results, we share our detailed protocol and workflow towards implementation of untargeted metabolomics in clinical practice to facilitate broader use of diagnostic metabolomics in the IMD community.
- Open Access
- 20 October 2025
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (1) , 108-118
Nanopore long-read sequencing for the critically ill facilitates ultrarapid diagnostics and urgent clinical decision making
Critically ill pediatric patients often have genetic disorders requiring a rapid diagnosis to guide urgent care decisions. Standard genetic testing typically takes weeks and requires multiple tests. Nanopore long-read genome sequencing (LR-GS) delivers genome-wide results within days as a one-test-fits-all solution. As one of the first centers in Europe, we implement ultrarapid LR-GS for critically ill patients. We enrolled 26 critically ill patients (median age 2 months) suspected of having a genetic disorder at the intensive care unit to perform (ultra)rapid nanopore LR-GS alongside standard genomic care. We compared diagnostic yield, turnaround time (TAT), and evaluated the impact on clinical decision making. In 11/26 cases a genetic diagnosis was made with (ultra)rapid LR-GS. From sample receipt to result, the average TAT was 5.3 days (range 2.0–10.8) for LR-GS and 18.4 days (range 6.1–29.1) for standard genomic care. DNA methylation analysis from LR-GS expedited the diagnosis in 3/26 cases. In 7/11 solved cases ultrarapid LR-GS led to immediate adjustments in patient care, e.g., medication switch or termination of treatment. Our findings underscore the clinical impact of ultrarapid LR-GS, including added value of methylation analysis, for critically ill patients and highlight existing challenges, paving the way to ultrarapid LR-GS integration into standard diagnostics.
- 20 October 2025
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (1) , 108-118
Open AccessNanopore long-read sequencing for the critically ill facilitates ultrarapid diagnostics and urgent clinical decision making
Critically ill pediatric patients often have genetic disorders requiring a rapid diagnosis to guide urgent care decisions. Standard genetic testing typically takes weeks and requires multiple tests. Nanopore long-read genome sequencing (LR-GS) delivers genome-wide results within days as a one-test-fits-all solution. As one of the first centers in Europe, we implement ultrarapid LR-GS for critically ill patients. We enrolled 26 critically ill patients (median age 2 months) suspected of having a genetic disorder at the intensive care unit to perform (ultra)rapid nanopore LR-GS alongside standard genomic care. We compared diagnostic yield, turnaround time (TAT), and evaluated the impact on clinical decision making. In 11/26 cases a genetic diagnosis was made with (ultra)rapid LR-GS. From sample receipt to result, the average TAT was 5.3 days (range 2.0–10.8) for LR-GS and 18.4 days (range 6.1–29.1) for standard genomic care. DNA methylation analysis from LR-GS expedited the diagnosis in 3/26 cases. In 7/11 solved cases ultrarapid LR-GS led to immediate adjustments in patient care, e.g., medication switch or termination of treatment. Our findings underscore the clinical impact of ultrarapid LR-GS, including added value of methylation analysis, for critically ill patients and highlight existing challenges, paving the way to ultrarapid LR-GS integration into standard diagnostics.